The goal of the learning health system is to improve based on the experiences of every participant, sharing research knowledge to drive a “person-centered future of health,” says LHC CEO.
The pharmaceutical and biotech consultancy has opened a new office in Dublin, Ireland ahead of Brexit, the final outcomes of which remain unknown, says CEO.
Clinical trial sites are challenged by fragmented financial processes, according to a new study by the Society of Clinical Research sites and Greenphire released this week at SCOPE 2019.
Artificial intelligence advances threaten data privacy, according to a new study, which found it is possible to re-identify individuals using their physical activity data.
The EMA needs to fix problems with the clinical trial registry to improve reporting across Europe, says TranspariMED founder, as seemingly small issues can “seriously hinder compliance.”
The industry has advanced to a point that should justify the financial investment in new technology, though uncertainty, and a lack of support, are hindering movement.
People on the move in January include new CEOs at Lonza, Taconic, MaSTherCell, Pii, and Wasdell, among several other c-suite shakeups and new hires as the industry kicks off the New Year.
The UK-based private equity firm CBPE has purchased a majority stake in Simbec-Orion and will expand the CRO's reach both geographically and across all business units.
The global software provider is discounting its reporting software for academics, as universities globally struggle with compliance and face increasing pressure to publish clinical trial results.
The Wasdell Group’s new EU headquarters in Dundalk, Ireland is set to commence operations later this year as part of the company’s “proactive contingency plan” ahead of Brexit.
Digital health companies raked in more than $9.5bn as part of 698 global venture capital deals last year – with data analytics and mHealth apps leading the pack among the top-funded categories.
The UK Parliament is putting pressure on universities failing to publish data from clinical trials – with plans to question institutions later this year following a debrief with AllTrials, which will be monitoring compliance.
